How early is too early? Challenges in ART initiation and engaging in HIV care under Treat All in Rwanda—A qualitative study

Author:

Ross JonathanORCID,Ingabire CharlesORCID,Umwiza Francine,Gasana Josephine,Munyaneza Athanase,Murenzi Gad,Nsanzimana Sabin,Remera Eric,Akiyama Matthew J.,Anastos Kathryn M.,Adedimeji Adebola

Abstract

Introduction HIV treatment guidelines recommend that all people living with HIV (PLWH) initiate antiretroviral therapy (ART) as soon as possible after diagnosis (Treat All). As Treat All is more widely implemented, an increasing proportion of PLWH are likely to initiate ART when they are asymptomatic, and they may view the relative benefits and risks of ART differently than those initiating at more advanced disease stages. To date, patient perspectives of initiating care under Treat All in sub-Saharan Africa have not been well described. Methods From September 2018 to March 2019, we conducted individual, semi-structured, qualitative interviews with 37 patients receiving HIV care in two health centers in Kigali, Rwanda. Data were analyzed using a mixed deductive and inductive thematic analysis approach to describe perceived barriers to, facilitators of and acceptability of initiating and adhering to ART rapidly under Treat All. Results Of 37 participants, 27 were women and the median age was 31 years. Participants described feeling traumatized and overwhelmed by their HIV diagnosis, resulting in difficulty accepting their HIV status. Most were prescribed ART soon after diagnosis, yet fear of lifelong medication and severe side effects in the immediate period after initiating ART led to challenges adhering to therapy. Moreover, because many PLWH initiated ART while healthy, taking medications and attending appointments were visible signals of HIV status and highly stigmatizing. Nonetheless, many participants expressed enthusiasm for Treat All as a program that improved health as well as health equity. Conclusion For newly-diagnosed PLWH in Rwanda, initiating ART rapidly under Treat All presents logistical and emotional challenges despite the perceived benefits. Our findings suggest that optimizing early engagement in HIV care under Treat All requires early and ongoing intervention to reduce trauma and stigma, and promote both individual and community benefits of ART.

Funder

National Institute of Mental Health

National Institute of Allergy and Infectious Diseases

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. World Health Organization, Department of HIV/AIDS. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015 September 2015.

2. Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat All;N Ford;J Int AIDS Soc,2018

3. Changes in rapid HIV treatment initiation after national "treat all" policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis;O Tymejczyk;PLoS Med,2019

4. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection;INSIGHT START Study Group;N Engl J Med,2015

5. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa;TEMPRANO ANRS 12136 Study Group;N Engl J Med,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3